<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0017">
 <label>17</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Seftel</surname>
    <given-names>MD</given-names>
   </name>, 
   <name name-style="western">
    <surname>Kuruvilla</surname>
    <given-names>J</given-names>
   </name>, 
   <name name-style="western">
    <surname>Kouroukis</surname>
    <given-names>T</given-names>
   </name>, 
   <etal>et al.</etal>
  </person-group>
  <article-title>The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group</article-title>. 
  <source>Leuk Lymphoma</source>
  <year>2017</year>;
  <volume>58</volume>:
  <fpage>1358</fpage>–
  <lpage>65</lpage>.
  <pub-id pub-id-type="pmid">27750483</pub-id>
 </mixed-citation>
</ref>
